https://www.selleckchem.com/products/dac51.html
Approximately 40-50% of patients with cutaneous melanoma harbor point mutations in . BRAF and MEK inhibitors in combination are now a standard therapy for advanced -mutated melanoma. Nevertheless, survival rates with the combination are limited, highlighting the need for further therapeutic improvement and strategies to overcome primary and acquired resistance. Encorafenib, a highly selective BRAF inhibitor, was developed in combination with binimetinib, a potent, selective allosteric MEK1/2 inhibitor, to improve efficacy and tolerability
Beğen
Yorum Yap
Paylaş
